Javascript required
Skip to content Skip to sidebar Skip to footer
Home / Right to Try â€ëœremains a Bustã¢â‚¬â„¢ as Many Drug Makers Prefer Fda Reviews

Right to Try â€ëœremains a Bustã¢â‚¬â„¢ as Many Drug Makers Prefer Fda Reviews

  • Review
  • Open up Access
  • Published:

"Right-to-Attempt" experimental drugs: an overview

Journal of Translational Medicine volume xviii, Article number:253 (2020) Cite this article

  • 2773 Accesses

  • 1 Citations

  • 8 Altmetric

  • Metrics details

Abstruse

The "Right-to-Try" experimental drugs act passed by Donald Trump in 2018 provides an opportunity of early on admission to experimental drugs for the treatment of life-threatening diseases and a potential boon to many young and nether-capitalized biotechnology or pharmaceutical companies. The pros and cons of experimental drugs, including a number of "cutting border" scientific, clinical, and a number of synergistic approaches such as artificial intelligence, machine learning, big data, data refineries, electronic health records, information driven clinical decisions and risk mitigation are reviewed.

Background

Over a century ago, near medications were the "wild west" with alleged therapeutic benefits. Nigh such medications sold to the public offered negligible or no evidence-based therapeutic efficacy and safety to the patient at large, except the "placebo benefit"—and hope—at the best. The drugs were unregulated and sold to the public in the Us and many parts of the world. To protect the public against the sale of misbranded, mislabeled and/or adulterated foods and drugs, the US in 1906 enacted [one] the "Pure Food and Drug Act" and this resulted in the establishment of the federal agency, the Food and Drug Administration (FDA).

Historical overview

The "Right-to-Endeavour" experimental drugs, however, originated [ii,3,4] from the Abigail Alliance for Improve Access to Developmental Drugs versus von Eschenbach. Due to Abigail's loftier expression of EGFR, her oncologist recommended Abigail for her terminal head and neck cancer to try an investigational EGFR-targeted drug, C222 (Erbitux), which was and then undergoing clinical trial for the treatment of colorectal cancer. Due to her ineligibility to participate in the clinical trials and denial by the FDA, Abigail'due south male parent, Frank Burroughs sued the FDA in 2003 for access to the experimental drug, Erbitux, on the pretext that an investigational drug by terminally ill patients after phase I approval was a constitutional right. Abigail's tragic story was 1 of the primary precursors and a "catalyst" that inspired patients and non-patients, including advocacy groups for admission to unapproved therapies by the FDA.

In May 2018, President Donald Trump signed the "Right-to-Try" Act [5]. The legislation overcame many of the regulatory barriers, limited the risks to the sponsor while implementation of the act inherently burdened the sponsor. The "Right-to-Try" legislation is in essence a derivative of the Expanded Admission Programs (EAPs). Advocates such every bit patients, families, friends and advocacy groups of the "Right-to-Effort" legislation argue that the legislation is in line within the pre-existing framework of EAPs and that the legislation: (i) provides a "streamlined" avenue for making eligible drugs available to eligible patients with no other options; (ii) it increases patient's appointment; (three) it is a patient's journeying of self-actualization; (4) information technology empowers the patient nearly his or her own health, well-existence and quality of life; (v) it provides optimism and access to novel interventions with potential therapeutic benefits that may prolong life and ameliorate quality of life; and (vi) the patient tin can be treated in the USA with valuable family time, more comfort and fewer risks than being treated overseas. The critics, on the other hand, debate: (i) there is an inherent safety risk that may potentially crusade more impairment to the patient or even death than the benefit because the experimental drug did not undergo rigorous testing; (two) there is a lack of oversight by the FDA, except posting of the consolidated almanac summary written report; (iii) the patient in nearly cases has limited agreement of the informed consent due to complexity and confusion of the medical terminology used in the consent class; (four) there are therapeutic misconceptions combined with high expectations and optimism by the patient; (v) there is potentially a considerable financial brunt by the patient or the patient's family because payors currently do not provide coverage and deny hospice care; (6) in that location is a potential loss of trust in the regulatory agency, the sponsor and the health intendance provider; and (vii) there is a liability "amnesty" for the health-care provider, including the drug sponsor for potential negative outcomes of the treatment unless the medical provider and the sponsor were engaged in "gross negligence, reckless or "wilful misconduct."

Some of the major inherent limitations and oftentimes overlooked most the "Right-to-Try" experimental drugs are: (i) patient's vulnerability due to lack of oversight by the FDA; (ii) there is a lack of clinical report protocol, including the lack of sufficient statistical power to detect the intended effect(s); (iii) the information is collected in a "slice-meal"; and (iv) a lack of systematic reporting about efficacy and the rubber of the experimental drug that may potentially result in limited information for the wellness and condom of the public. Some of these issues may be addressed and resolved by utilizing EHR systems. EHR systems are maintained by health care providers and health care organizations for delivering patient intendance. EHR systems can thus easily lend themselves for integrating existent-time electronic health care data most the patient across multiple health care providers.

One of the most important considerations and occasionally overlooked is comorbidity; it is quite mutual amid cancer patients and it tin potentially bear on the treatment outcome, worsen the adverse effects due to polypharmacy and may fifty-fifty shorten the life. The prognosis of patients with comorbidity is often poor survival combined with poor quality of life and higher financial costs. The use of experimental drugs in patients with morbidity may thus be risky or limited unless the experimental drug has gone through farther rigorous testing and/or the experimental drug is paired synergistically with an FDA-approved drug and advisable tools are employed for monitoring efficacy and rubber of the therapy. Treatment of metastatic cancer patients with comorbidity using experimental drugs would be even more challenging and riskier with many implications that may warrant further considerations that are in the all-time interest of the patient's health, well-being and life, including boosted financial burden.

The "landscape, the ecosystem and the dynamics"

The implications of ethics, constabulary, regulations, regime policies, constitutional rights by final sick patients, patient advocacy groups, including stakeholders about the pros and cons echoed through the "ecosystem" of early access to investigational drugs. Nether the "Right-to-Effort" legislation, the eligibility to participate include: (i) the patient must accept been diagnosed with a debilitating or life-threatening disease; (ii) the patient must have failed all standard of care treatments; (iii) the experimental or the investigational drug must have completed at to the lowest degree phase 1 trial; (4) the patient must have signed an informed consent [6]; and (half dozen) the pharmaceutical company must be able to provide the experimental drug to the patient. Due to the potentially negative effect nigh the therapeutic efficacy combined with the safety bug, most sponsors developing medications for life-threatening diseases have had reservations about participating in expanded access or the "Right-to-Try" programs. To de-risk the potential negative outcomes and the implications combined with an opportunity to target a much larger number of patients than to a few eligible patients under the early on admission programs, the sponsors' chief goal has been to have full FDA approval of the drug. The drug blessing process, of form, is lengthy and highly risky due to potential clinical trial failures along each step of the approval process. It is an expensive process—currently, estimated to exist betwixt Usa$ 1.ix–2.v billion [7, 8].

On the other mitt, People's republic of china for almost ii decades approved a number of experimental drugs. From 2003 to 2005, the SFDA approved H101, experimental oncolytic viral therapy for head and neck cancer, an angiogenic Endostar inhibitor for treating non-small prison cell lung cancer and Gendicine for treating head and neck cancer [nine,ten,11]. Nevertheless, in December, 2019, the Drug Assistants Law (DAL) by the SFDA came into event [12]. The DAL is likely to have an impact on experimental drugs because it addresses several issues such as public health concerns, drug innovation, drug safety and drug accessibility. In the "wake" of the recent epidemics such as Ebola, MERS caused past coronavirus (MERS-CoV) and more recently the outbreak of the coronavirus, SARS-CoV2 in 2019–2020, the use of "emergency drugs and compassionate utilize of experiential drugs" may warrant farther considerations and the options available in an epidemic or a pandemic. Gilead Sciences' experimental drug (at the time of writing), remdesivir, is one of the well-nigh promising drug candidates that may be effective against SARS-CoV2. The drug exhibits broad-spectrum antiviral activeness against a number of RNA viruses including the Ebola virus by interfering with the viral polymerase enzyme. Remdesivir is currently beingness used as an "emergency experimental drug" on compassionate basis while randomized controlled studies are underway [thirteen].

The risks and benefits of phase 1 oncology trials from 1991 to 2002 accept been reviewed [xiv] involving a total of 460 trials and 11,935 participants. The participants were tested for toxicity and ten,402 participants were assessed for therapeutic efficacy. The overall response rate was reported to be x.6% with considerable variations amidst trials. The classic stage 1 trials using single investigational chemotherapeutic drug represented 20% of the trials with a response charge per unit of 4.4%. On the other mitt, the trials that included at least ane FDA-approved anticancer drug consisted of 46.3% of the trials and the response charge per unit was 17.viii%. The overall death due to toxicity was constitute to be 0.49%. The above written report demonstrated the value and merits such equally higher efficacy and condom due to a lower expiry rate if the investigational drug is combined with at least i FDA-approved anticancer drug. Some of the most recently phase 1/Ii completed studies (at the time of writing) are exemplified in Table i [xv] and the drugs are potential experimental drug candidates.

Table 1 Example of anti-cancer drugs phase I/2 completed studies

Total size table

Integrative synergistic approaches

Some of the most emerging and promising tools being adult and increasingly being used in the health intendance-related sectors include data warehouse, that is a repository of historical data from data warehouses to data refineries for refining the crude data dubbed as the "oil of the digital era" into valuable data all the way from research to clinical utilise [xvi, 17]. Because the data in the raw form is enormous, complex, lacks structure and standardization combined with interoperability bug, compliance issues and upstanding challenges, the data refineries are envisioned to bridge the gap for refining and distilling the data on its journeying from research to clinical utility for the benefits of the patients, including the stakeholders.

To navigate the costly and complex mural of therapeutic drugs from basic inquiry to clinical utilise hinges on integrating multi-disciplinary approaches. Considering of different goals of the stakeholders, it has been historically challenging to strike a common chord that resonates beyond the whole ecosystem. Over the final few years, there has been a prototype shift due to many factors such every bit the high cost of drug development, lengthy approval process, closer collaborations betwixt academia and industries, integration of emerging technologies such every bit digital health, telehealth and wearables, gene editing, including big data, funding, education, and changes in authorities policies. The health benefits of panomics (genomics, proteomics, transcriptomics, metabolomics, epigenomics, ionomics and microbiomics) and the increasing apply of panomics in personalizing medicine are emerging and promising in the treatment of diseases such as cancer, cardiovascular and gastrointestinal disorders [18, 19]. The integral role of "gut" microbiome in health and in treating many diseases, including cancer is get-go to emerge as demonstrated by immune checkpoint inhibitor therapy [20, 21]. While panomics addresses many of the precision medicine handling benefits, it falls short in addressing bug such as the multi-morbidity, impact of the illness on the patients' lives, their adaptability to the affliction or other existing diseases, their family, their social life and their customs life. Personomics is thus envisioned to span the gap between panomics and the patients' personal or an individual's circumstances [22]. This "echoes" with the words of Sir William Osler: "the good physician treats the illness; the great dr. treats the patient who has the illness" [23].

The Precision Medicine Initiative (PMI) launched in 2015 [24] has been edifice to a "crescendo" and its affect on drug evolution, clinical trials and in personalizing the treatment for therapeutic efficacy, maximum safety, higher durable response, longevity and college quality of life is emerging. Over the last few years, the FDA has emphasized the use of real-globe data (RWD) and real-world evidence (RWE) to modernize clinical trials, an advocacy made possible by the 21st Century Cures Deed [25, 26]. With real-globe data and real-evidence, researchers will be able to go across the scope of traditional trials, transition to a "hybrid" trial that is dynamic, providing insights from information collected in clinical care. As an example, the FDA in Apr 2019 approved a supplemental New Drug Application based on data extracted from EHR and post-marketing reports of the real-world use of Pfizer's drug, IBRANCE (Palbociclib) to expand the indication for in combination with Fulvestrant to include men with hormone receptor positive (HR+), human being EGFR ii negative (HER2−) advanced or metastatic breast cancer, for the treatment of breast cancer in men [27, 28]. The old FDA Commissioner, Dr. Scott Gottlieb stated [29]: "the EHRs and other data sources, paired with advances in machine learning, will be crucial for architecting the side by side generation of successful clinical trials.

To address many of the challenges of implementing genomics medicine for routine apply, the NIH funded IGNITE Network with the goals of integrating genomic information into EHR [xxx]. The IGNITE Network deploys plethoric "tools" for "Point-of-Care Decisions", genetic markers for illness risk prediction including prevention, tools about family history information, pharmacogenomics information and refinement of disease diagnosis. Similarly, IBM Watson Health in collaboration with Brigham and Women Hospital and Vanderbilt University Medical Center has been pursuing the utilise of artificial intelligence for supporting precision medicine, to heighten patient condom, to nurture wellness equity, to expand and amend EHR usability [31]. Furthermore, the Watson Studio and Watson Noesis Catalog has the information refinery tool for processing and transforming large amounts of raw data into valuable and clinical useful information for analytics. Several governments across the world, organizations, academia and institutes have created open access networks such as the Cancer Biomedical Informatics Grid (caBIG) and the Cancer Translational Research Informatics Grid (caTrip) for the caBIG project with a focus and a mission near driving translational research and improving the patient outcome by linking network of researchers, patients and physicians [32]. Similarly authorities and non-government sponsored programs have been established and they have been mushrooming globally such as the ICPerMed and the ECMC in the U.k. that back up biotech and pharmaceutical companies to develop drugs in oncology through strategic partnerships [33]. Examples of programs in the The states include: the National Eye for Advancing Translational Sciences (NCATS) at the National Institutes of Wellness (NIH), the NCI-MATCH, a precision medicine cancer handling clinical trial that is co-led by National Cancer Found (NCI) and the ECOG-ACRIN Cancer Research Group. In the NCI-Lucifer trial, patients received therapy based on the genetic changes institute in their tumor as exemplified by the results from Arm H of the study demonstrated that treatment with a "cocktail" of dabrafenib and trametinib, designed to target cancers that have specific BRAF factor mutations, was effective in a trial of 35 patients having 17 distinct tumor types [34]. Well-nigh recently, the studies [35] published by the Pan-cancer Analysis of Whole Genome (PCAWG) consortium involving whole genome sequencing of 2658 cancer genomes demonstrated new information about cancer drivers from 38 tumor types and identified potentially new targets for precision medicine.

The exploitation of such tools for the "Correct-to-Try" experimental drugs in treating life threatening diseases such every bit cancer will well-nigh probable favor the outcome and mitigate the negative outcomes associated with the clinical utilise of experimental drugs. The outcome using experimental drug has the potential to exist more favorable if combined ("erect-tail") with an FDA-approved drug. Some of the other approaches include implementation of programs and policies that incorporate the interests of patients such as education, understanding of risks, second opinion about the therapy, expectations and costs due to potential complications, education of physicians nigh precision medicine and emerging tools, dosing, the use of EHR, systematic reporting of results that may be important for public health and safety. The sponsor should provide transparency and firsthand notifications to the md including the FDA most safe problems during the drug development stage and any manufacturing or supply issues. Due to the complexity of the informed consent form and lack of oversight by the FDA, it is important that an independent or a neutral body such equally an IRB or an ethics committee is engaged in reviewing the consent procedures. The positive outcome of the treatment results will thus exist a potential benefaction to young biotech and pharmaceutical companies facing the "valley of decease" syndrome, struggling to raise funding or looking for partnerships or trying to build trust and credibility. Furthermore, a positive issue has the potential to spawn new ventures or opportunities such as veterinary oncology and "outpatient" clinics.

Information technology is envisioned that the use of new tools encompassing electronic medical records, personalized medicine, data refineries, artificial intelligence and machine learning, further testing of drugs, including adjuvant therapies or "cocktail" of drugs volition favor the issue of experimental drugs and may pave the fashion for indication expansion as exemplified past IBRANCE. Furthermore, the utilise of such tools are expected to: (i) accelerate drug development time; (ii) reduce drug evolution toll; (three) lower the cost of drugs; (iv) meliorate the durable response; (v) reduce adverse furnishings such every bit hepato-and cardio-toxicity; (vi) improve longevity and quality of life of the patient.

Conclusion

The progress made on several fronts in healthcare and the concerted efforts by the stakeholders, including the integral role of agencies such every bit World Health Organization (WHO) and Global Health Quango (GHC) over the last few decades for the treatment of diseases, patient and public engagements, the part of healthcare practitioners, the role of educational activity, data ownership, data sharing, transparency, privacy, ethics, standardization across the multi-industries, regulations, compliance, funding of programs, payment past medical insurance companies, including global policy development and implementation currently present limited opportunities and many challenges for the "Correct-to-Try" experimental drugs for the treatment of life-threatening diseases. The "Right-to-Try" experimental drug is withal a major "milestone" along the journey and its full impact on treating life-threatening diseases such every bit cancer and infectious diseases such as COVID-19 remain to be seen. Ane of the biggest impacts of emergency use of experimental drugs and empathetic drugs or "repurposing" of drugs is unfolding during the current coronavirus pandemic crisis.

Availability of data and materials

Data sharing is not applicative to this commodity considering no data sets were generated and/or analyzed for the study.

Abbreviations

ECMC:

Experimental Cancer Medicine Eye

EGFR:

Epidermal growth factor receptor

EHR:

Electronic wellness tape

HER2:

Human epidermal growth factor receptor 2

IRB:

Institutional review board

MERS:

Eye East respiratory syndrome

RNA:

Ribonucleic acid

SFDA:

State Food and Drug Administration (China)

References

  1. Kantor AF. Upton Sinclair and the Pure Food and Drugs Act of 1906: 'I aimed at the public'south heart and past blow I striking it in the stomach. Am J Public Wellness. 1976;66(12):1202–5.

    CAS  Commodity  Google Scholar

  2. Jacobson PD, Parmet Nosotros. A new era of unapproved drugs: the instance of Abigail Alliance 5 Von Eschenbach. JAMA. 2007;297(2):205–eight.

    CAS  Article  Google Scholar

  3. Mackey TK, Schoenfeld VJ. Getting 'social' to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. BMC Med. 2016;fourteen:17–26.

    Article  Google Scholar

  4. https://www.abigail-alliance.org/story.php. Accessed 5 December 2019.

  5. Own D. Trump signs bill to give patients right to try drugs. BMJ. 2018;361:k2429.

    Google Scholar

  6. Piel J. Informed consent in right-to-try cases. J Am Acad Psychiatry Police. 2016;44(3):290–half-dozen.

    PubMed  Google Scholar

  7. DiMasi JA, Grabowskib HG, Hansenc RW. Innovation in the pharmaceutical manufacture: new estimates of R&D costs. J Health Econ. 2016;47:20–33.

    Article  Google Scholar

  8. Mestre-Ferrandiz J, Sussex J, Towse A. The R&D cost of new medicine. 2012. https://www.ohe.org/publications/rd-price-new-medicine. Accessed 7 Feb 2020.

  9. Tysome JR, Lemoine NR, Wang Y. Update on oncolytic viral therapy—targeting angiogenesis. Onco Targets Ther. 2013;6:1031–40.

    CAS  Article  Google Scholar

  10. Jia H, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol. 2006;24:117–viii.

    CAS  Article  Google Scholar

  11. Zhang Westward, Li L, Li D, Liu J, Li X, Li W, Xu X, Zhang MJ, Chandler LA, Lin H, Hu A, Xu W, Lam DM. The first canonical gene therapy product for cancer Ad-p53 (gendicine): 12 years in the clinic. Hum Gene Ther. 2018;29(2):160–79.

    CAS  Article  Google Scholar

  12. China's New Drug Assistants Law frames a promising regulatory mural. 2019; 23:12. https://world wide web.asiabiotech.com/23/2312/23120020x.html.

  13. https://www.gilead.com/purpose/advancing-global-health/covid-xix. Accessed 13 May 2020.

  14. Horstmann East, McCabe K, Grochow L, Yamamoto S, Rubinstein Fifty, Budd T, Shoemaker D, Emanuel Due east, Grady C. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352:895–900.

    CAS  Article  Google Scholar

  15. https://clinicaltrials.gov/ct2/results?recrs=ab&cond=Lung+Cancer&term=&cntry=U.s.&state=&urban center=&dist=. Accessed vii Feb 2020.

  16. Boussadi A, Caruba T, Zapletal E, Sabatie BR, Durieux P, Patrice Degoulet P. A clinical information warehouse-based process for refining medication orders alerts. J Am Med Inform Assoc. 2012;19(v):782–5.

    Article  Google Scholar

  17. Using Watson Studio and Knowledge Catalog, Data Refinery saves data grooming time by quickly transforming large amounts of raw information into consumable quality information. https://www.ibm.com/cloud/data-refinery?p1=Search&p4=p50367843279&p5=b&p1=Search&p4=p50367843279&p5=b&p1=Search&p4=p50367843279&p5=b&cm_mmc=Search_Bing-_-1S_1S-_-WW_NA-_-%2Bdata%20%2Brefinery_b&cm_mmca7=71700000060884993&cm_mmca8=kwd-81226564052940:aud-807596473:loc-71283&cm_mmca9=CKT45PeiqOgCFQKrxQIdMe0EFA&cm_mmca10=81226482883052&cm_mmca11=b&&utm_source=bing&utm_medium=cpc&utm_campaign=Search%7CAI%7CLower%7CWW%7CNA%7CGeneric%7CEN%7CBMM&utm_term=%2Bdata%xx%2Brefinery&utm_content=Data%20Refinery_Data%20Refinery_Generic_BMM_NULL&gclid=CKT45PeiqOgCFQKrxQIdMe0EFA&gclsrc=ds.

  18. Sandhu C, Qureshi A, Emili Due east. Panomics for precision medicine. Trends Mol Med. 2018;24(1):85–101.

    Article  Google Scholar

  19. Hasin Y, Seldin Grand, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;xviii:83. https://doi.org/10.1186/s13059-017-1215-ane.

    CAS  Article  PubMed  PubMed Central  Google Scholar

  20. Yi G, Yu S, Qin S, Liu Q, Xu H, Zhao W, Chu Q, Wu Yard. Gut microbiome modulates efficacy of allowed checkpoint inhibitors. J Hematol Oncol. 2018;11:47.

    Article  Google Scholar

  21. Gopalakrishnan 5, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018;33(4):570–80. https://doi.org/10.1016/j.ccell.2018.03.015.

    CAS  Article  PubMed  PubMed Fundamental  Google Scholar

  22. Moor Yard, Heukels P, Kool Yard, Wijsenbeek G. Integrating patient perspectives into personalized medicine in idiopathic pulmonary fibrosis. https://www.researchgate.internet/publication/321945065. Accessed nine Jan 2020.

  23. American College of Physicians. "Sir William osler and internal medicine". https://www.acponline.org/about-acp/about-internal-medicine/sir-william-osler-and-internal-medicine. Accessed xi Jan 2020.

  24. Rothstein MA. Some lingering concerns about the precision medicine initiative: currents in contemporary bioethics. J Law Med Ideals. 2016;44(3):520–5.

    Article  Google Scholar

  25. Real-world evidence. FDA. http://www.fda.gov. Accessed 24 Mar 2020.

  26. 21st Centuary Cures Deed. https://www.fda.gov/regulatory-data/selected-amendments-fdc-act/21st-century-cures-act. Accessed iii Feb 2020.

  27. Updated data from phase 3 trial of Ibrance (palbocicilib) plus letrozole in ER+, HER2− metastatic breast cancer confirm improvement in progression-free survival. https://www.pfizer.com/news/press-release/press-release-particular/updated_data_from_phase_3_trial_of_ibrance_palbociclib_plus_letrozole_in_er_her2_metastatic_breast_cancer_confirm_improvement_in_progression_free_survival. Accessed 8 Mar 2020.

  28. Taylor-Stokes G, Mitra D, Waller J, Gibson Thou, Milligan G, Iyer Due south. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in existent-earth settings in the The states: results from the IRIS study. Breast. 2019;43:22–7. https://doi.org/10.1016/j.chest.2018.10.009.

    Commodity  PubMed  Google Scholar

  29. Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA'due south new strategic framework to advance apply of real-globe testify to support development of drugs and biologics. https://www.fda.gov/news-events/press-announcements/argument-fda-commissioner-scott-gottlieb-md-fdas-new-strategic-framework-advance-employ-existent-world. Accessed eight Mar 2020.

  30. Implementing Genomics in Practice. https://gmkb.org/. Accessed 2 Mar 2020.

  31. David Raths. IBM Watson Teams with Vanderbilt, Brigham and women'south. Applying AI to improve utility EHR, claims information to address public health issues. 2019. https://www.hcinnovationgroup.com/analytics-ai/artifical-intelligence-machine-learning/news/21068437/ibm-watson-teams-with-vanderbilt-brigham-and-womens. Accessed 22 Feb 2020.

  32. McConnell P, Dash RC, Chilukuri R, Pietrobon R, Johnson K, Annechianrico R, Cuticchia JA. The cancer translational research informatics platform. BMC Med Inform Decis Mak. 2008;viii:60. https://doi.org/10.1186/1472-6947-viii-60.

    Article  PubMed  PubMed Primal  Google Scholar

  33. https://www.ecmcnetwork.org.uk/. Accessed 4 Jan 2020.

  34. Jessica Kent. NIH precision medicine trial releases cancer written report. 2019. https://healthitanalytics.com/news/nih-precision-medicine-trial-releases-cancer-study-results. Accessed eighteen January 2020.

  35. Pan-cancer analysis of whole genomes. Nature. 2020;578:82–93. https://doi.org/10.1038/s41586-020-1969-6.

Download references

Acknowledgements

The author of the article is acting individually and independently.

Funding

NA because the author is currently not funded by grant from whatever government and/or individual establishment/organization.

Author information

Affiliations

  1. MediLite Diagnostika, Inc, 12364 Carmel Country Rd, San Diego, CA, 92130, USA

    Vijay Mahant

Contributions

The writer is the only contributor to writing/drafting the manuscript and the appropriate references accept been cited/acknowledged. The author read and canonical the concluding manuscript.

Respective author

Correspondence to Vijay Mahant.

Ethics declarations

Ethics approving and consent to participate

Not applicative because the manuscript did not involve studies involving homo and/or animate being participants or human data or tissues).

Consent for publication

Non applicable because the manuscript does not have individual's data and/or images).

Competing interests

The writer declare that at that place is no competing interest.

Additional information

Publisher'southward Annotation

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Artistic Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, equally long as yous give appropriate credit to the original author(due south) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party cloth in this commodity are included in the commodity's Artistic Commons licence, unless indicated otherwise in a credit line to the material. If fabric is not included in the article's Creative Commons licence and your intended utilize is non permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Artistic Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this commodity, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this commodity

Verify currency and authenticity via CrossMark

Cite this article

Mahant, 5. "Right-to-Endeavour" experimental drugs: an overview. J Transl Med 18, 253 (2020). https://doi.org/x.1186/s12967-020-02427-iv

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI : https://doi.org/10.1186/s12967-020-02427-4

Keywords

  • "Right-to-Endeavour" experimental drugs
  • Precision medicine
  • EHR
  • Artificial intelligence
  • Machine learning
  • Panomics
  • RWD
  • RWE
  • caTrip and caBIG

voigthapterk48.blogspot.com

Source: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02427-4